ALNY News and Press, Alnylam Pharmaceuticals Inc. From 01/04/22

– Consistent Scientific Leadership Focused on Sustainable Innovation – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined A...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40 th Annual J.P. Morgan Healthcare Conference, being held virtually, on Monday, January 10, 2022 at 9:45 am ET. This prese...

BridgeBio Pharma (NASDAQ:BBIO) perks up 3% premarket after shedding around 72% during yesterday's intrady session after its late-stage study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint. Following this news, sever...

Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...

Gainers: Microbot Medical (NASDAQ:MBOT) +51%, CollPlant Biotechnologies (NASDAQ:CLGN) +27%, Lucira Health (NASDAQ:LHDX) +14%, IceCure Medical (NASDAQ:ICCM) +13%, Cue Health (NASDAQ:HLTH) +12%. Losers: BridgeBio Pharma (NASDAQ:BBIO) -71%, Biond...

The FDA has approved Leqvio (inclisiran) — developed by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Novartis (NYSE:NVS) — to lower low-density lipoprotein cholesterol. In the U.S., Leqvio is the fourth small interfering RNA (siRNA) therapy and the first indicated to reduce lipopro...

– Leqvio ® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the ...

Alnylam Pharmaceuticals (ALNY -5.0%) is trading lower despite the company’s newly announced plans to begin an early-stage study for its Alzheimer’s disease (AD) candidate, ALN-APP. Cambridge, Massachusetts-based Alnylam (NASDAQ:ALNY), focused on RNAi therapeutics, has already su...

- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi Therapeutic Program for CNS Disease and Represents the Start of Aln...

– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics co...